Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Natasha Martin

    TitleAssociate Professor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    Address9500 Gilman Drive #0507
    CA La Jolla 92093
    Phone858-822-4802
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      Modeling Structural HIV Determinants in Substance Users and related populations
      NIH R01DA037773Apr 1, 2015 - Dec 31, 2017
      Role: Principal Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Higgins JP, Soares-Weiser K, López-López JA, Kakourou A, Chaplin K, Christensen H, Martin N, Sterne JA, Reingold AL. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016 Oct 13; 355:i5170. PMID: 27737834.
        View in: PubMed
      2. Fraser H, Mukandavire C, Martin N, Hickman M, Cohen MS, Miller WC, Vickerman P. HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidence. Int J Epidemiol. 2016 Aug 14. PMID: 27524816.
        View in: PubMed
      3. Hickman M, Martin N, Huxtable R. Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs. Addiction. 2017 Feb; 112(2):201-203. PMID: 27514647.
        View in: PubMed
      4. Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, Taxman FS, El-Bassel N, Martin N, Booth R, Stöver H, Dolan K, Vickerman P. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016 Sep 17; 388(10050):1228-48. PMID: 27427455.
        View in: PubMed
      5. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Mohd Hanafiah K, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin N, Mokdad AA, Mokdad AH, Murray CJ, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016 Sep 10; 388(10049):1081-8. PMID: 27394647.
        View in: PubMed
      6. Martin N, Vickerman P, Hickman M. Reply. Hepatology. 2016 Nov; 64(5):1822-1823. PMID: 27112633.
        View in: PubMed
      7. Stone J, Martin N, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? PLoS One. 2016; 11(5):e0156213. PMID: 27224423.
        View in: PubMed
      8. Martin N, Vickerman P, Hickman M, Patterson TL, Rand E, Abramovitz D, Strathdee SA. Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV prevention. Addiction. 2016 Sep; 111(9):1512-5. PMID: 27075692.
        View in: PubMed
      9. Martin N, Vickerman P, Brew IF, Williamson J, Miners A, Irving WL, Saksena S, Hutchinson SJ, Mandal S, O'Moore E, Hickman M. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology. 2016 Jun; 63(6):1796-808. PMID: 26864802.
        View in: PubMed
      10. Martin N, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, Martin TC, Delpech V, Ruf M, Price H, Azad Y, Thomson EC, Vickerman P. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clin Infect Dis. 2016 May 1; 62(9):1072-80. PMID: 26908813.
        View in: PubMed
      11. Martin N, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, Foster GR, Hutchinson SJ, Goldberg DJ, Martin TC, Ramsay M. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol. 2016 Jul; 65(1):17-25. PMID: 26867489.
        View in: PubMed
      12. Geue C, Wu O, Xin Y, Heggie R, Hutchinson S, Martin N, Fenwick E, Goldberg D. Cost-Effectiveness of HBV and HCV Screening Strategies - A Systematic Review of Existing Modelling Techniques. PLoS One. 2015; 10(12):e0145022. PMID: 26689908.
        View in: PubMed
      13. Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin N. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis. 2015 Dec; 28(6):576-82. PMID: 26524330.
        View in: PubMed
      14. Martin N, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS. 2015 Sep; 10(5):374-80. PMID: 26248124.
        View in: PubMed
      15. Scott N, McBryde E, Vickerman P, Martin N, Stone J, Drummer H, Hellard M. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med. 2015; 13:198. PMID: 26289050.
        View in: PubMed
      16. Pines HA, Patterson TL, Rangel G, Martinez G, Bazzi AR, Ulibarri MD, Syvertsen JL, Martin N, Strathdee SA. STI/HIV test result disclosure between female sex workers and their primary, non-commercial male partners in two Mexico-US border cities: a prospective study. Sex Transm Infect. 2015 May; 91(3):207-13. PMID: 25298381.
        View in: PubMed
      17. Panovska-Griffiths J, Vassall A, Prudden HJ, Lépine A, Boily MC, Chandrashekar S, Mitchell KM, Beattie TS, Alary M, Martin N, Vickerman P. Optimal allocation of resources in female sex worker targeted HIV prevention interventions: model insights from Avahan in South India. PLoS One. 2014; 9(10):e107066. PMID: 25271808.
        View in: PubMed
      18. Martin N, Vickerman P, Goldberg D, Hickman M. HCV treatment as prevention in prison: Key issues. Hepatology. 2015 Jan; 61(1):402-3. PMID: 24797358.
        View in: PubMed
      19. Martin N, Devine A, Eaton JW, Miners A, Hallett TB, Foster GR, Dore GJ, Easterbrook PJ, Legood R, Vickerman P. Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa. AIDS. 2014 Jan; 28 Suppl 1:S35-46. PMID: 24468945.
        View in: PubMed
      20. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin N, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2014 Jan; 2(1):e23-34. PMID: 25104632.
        View in: PubMed
      21. Martin TC, Martin N, Hickman M, Vickerman P, Page EE, Everett R, Gazzard BG, Nelson M. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS. 2013 Oct 23; 27(16):2551-7. PMID: 23736152.
        View in: PubMed
      22. Martin N, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, Hickman M. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013 Nov; 58(5):1598-609. PMID: 23553643.
        View in: PubMed
      23. Martin N, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open. 2013; 3(8). PMID: 23943776.
        View in: PubMed
      24. Martin N, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013 Aug; 57 Suppl 2:S39-45. PMID: 23884064.
        View in: PubMed
      25. Martin TC, Martin N, Naresh KN, Nelson M. Atraumatic splenic rupture secondary to chronic HIV infection. Int J STD AIDS. 2013 Dec; 24(12):989-91. PMID: 23970617.
        View in: PubMed
      26. Martin N, Vickerman P, Miners A, Hickman M. How cost-effective is hepatitis C virus treatment for people who inject drugs? J Gastroenterol Hepatol. 2013 Apr; 28(4):590-2. PMID: 23527756.
        View in: PubMed
      27. Vickerman P, Martin N, Roy A, Beattie T. Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Depend. 2013 Sep 1; 132(1-2):172-81. PMID: 23453261.
        View in: PubMed
      28. Hellard ME, Jenkinson R, Higgs P, Stoové MA, Sacks-Davis R, Gold J, Hickman M, Vickerman P, Martin N. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust. 2012 Jun 4; 196(10):638-41. PMID: 22676879.
        View in: PubMed
      29. Martin N, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012 Jan; 55(1):49-57. PMID: 21898506.
        View in: PubMed
      30. Vickerman P, Martin N, Hickman M. Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings--implications for intervention impact. Drug Alcohol Depend. 2012 Jun 1; 123(1-3):122-31. PMID: 22138540.
        View in: PubMed
      31. Martin N, Pitcher AB, Vickerman P, Vassall A, Hickman M. Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One. 2011; 6(8):e22309. PMID: 21853030.
        View in: PubMed
      32. Martin N, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011 Jun; 54(6):1137-44. PMID: 21145810.
        View in: PubMed
      33. Martin N, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol. 2011 Apr 7; 274(1):58-66. PMID: 21236265.
        View in: PubMed
      Natasha's Networks
      Concepts
      Derived automatically from this person's publications.
      See all (64) concept(s)
      _
      Co-Authors
      People in Profiles who have published with this person.
      See all (4) people
      _
      Similar People
      People who share similar concepts with this person.
      See all (60) people
      _
      Same Department
      Search Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _